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Penile Rehabilitation Following Radical Prostatectomy
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With the emergence of prostate-specific antigen testing, a substantial drop in pa-
tient age at the diagnosis of prostate cancer is well recognized, and the detection of 
lower-volume and relatively more localized cancers has elevated biochemical cure 
rates of prostate cancer when treated by radical prostatectomy (RP). After operation, 
erectile dysfunction (ED) can become a troublesome issue affecting significantly the 
quality of life of some patients. The concept of early penile rehabilitation following 
RP started in the 1990s. There is evidence suggesting that lack of erections after RP 
will produce cavernous hypoxia resulting in cavernous fibrosis causing subsequent 
penile shrinkage and veno-occlusive dysfunction, which taken together will hinder the 
recovery of spontaneous erection. The main goal of penile rehabilitation is thus to pre-
vent the unwelcome cascade. Various treatment modalities for ED have been at-
tempted to serve the purpose. Initial studies showed that intracavernous injection of 
vasoactive agents was beneficial. Later, the use of vacuum constriction devices (VCDs) 
and phosphodiesterase type 5 (PDE5) inhibitors were also found to be of help. These 
treatment options have their own advantages and disadvantages. The present article 
gives a brief overview of penile rehabilitation following RP.
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1. Introduction
In the recent few decades, radical prostatectomy (RP) has 
been the “gold standard” treatment for organ-confined 
prostate cancer, offering a good chance of cure of the dis-
ease. Yet, erectile dysfunction (ED) following RP remains 
an important quality of life concern for men undergoing 
RP. ED is estimated to affect 26–100% of patients after 
the surgery.1 In spite of advancements in surgical tech-
niques mainly focusing on preserving the neurovascular 
bundle, a substantial number of men undergoing RP still 
have postoperative ED.2 Considering that men with pros-
tate cancer are diagnosed at relatively younger ages in the 
era of serum prostatic-specific antigen testing, ED after RP 
deserves even more attention.
Mechanisms of ED after RP have been suggested to 
be due to postoperative changes in the corpus cavernosa 
like neuropraxia, ischemic and hypoxic insults, fibrotic 
remodeling, and apoptosis.3–6 These events can occur 
even when the nerve-sparing techniques are applied. In 
order to maximally uphold the preoperative erectile 
function, surgeons should individualize the procedure 
and preserve as much of the neurovascular bundle as 
possible during the operation. Furthermore, excessive 
mechanical stretch and thermal injury from electrocau-
tery to the neurovascular bundle should be avoided to 
prevent insults, ischemia, and inflammation. The so-called 
energy-free nerve-sparing RP procedure has been advo-
cated by several investigators in recent years.7,8 In addition, 
intraoperative use of real-time transrectal ultrasonography 
and cavernous nerve stimulation is suggested to be of help 
in preserving the neurovascular bundle.9–12 Finally, nerve 
grafting and alginate gel sponge sheet placement have 
both been demonstrated to be effective in accelerating 
cavernous nerve regeneration.13,14
The idea of penile rehabilitation was first described 
by Montorsi et al.15 in 1997, showing that early use of 
intracavernous injection (ICI) of alprostadil was effective 
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in helping to restore erectile function in patients receiving 
RP. Since then, various attempts have been employed 
aiming to assist erectile function recovery after RP. There 
are still no generally accepted guidelines for penile reha-
bilitation after RP at the present time; however, the goal 
of penile rehabilitation is clear, that is to use erectogenic 
aids to improve the cavernous oxygen circulation and 
maintain the structure of the corporeal bodies, giving the 
penis a better chance of restoring spontaneous erection.16 
In other words, it is hoped that cavernous smooth muscle 
cell fibrosis and apoptosis resulting from lack of postopera-
tive erection and cavernous hypoxia are minimized through 
the implementation of penile rehabilitation.
2.  ICI of Vasoactive Agents for Penile 
Rehabilitation
ICI of vasoactive agents can increase blood flow into the 
cavernous space via mechanisms like increasing cyclic 
adenosine monophosphate, antagonizing α-adrenergic 
receptors, and relaxing the cavernous smooth muscle di-
rectly. The effects of ICI on cavernous smooth muscle do 
not require an intact nervous system to induce erections. 
Therefore, this regimen can be applied to men who have 
not undergone nerve-sparing surgery.
Montorsi et al.15 investigated whether ICI of vasoac-
tive agents could improve the erectile function of the 
post-prostatectomy men in a randomized trial, in which 
30 men with preoperative potency were randomized 
into two groups. One group received ICI of alprostadil 
three times a week after the operation and the other 
group (control group) did not. At 12 weeks, 67% of men 
in the group receiving ICI had spontaneous erections 
sufficient for penetration compared with 20% in the 
control group. Mulhall et al.17 conducted a trial rando-
mizing post-prostatectomy 132 men into a penile reha-
bilitation group (58 men) and a no-penile rehabilitation 
group (74 men). The rehabilitation group used either 
sildenafil or ICI three times a week. Analyses of the re-
sults at 18 months revealed that 52% of men in the reha-
bilitation group were able to have functional erections, 
compared with 19% of men in the no-penile rehabilitation 
group.
3.  Vacuum Constriction Devices For Penile 
Rehabilitation
Vacuum constriction devices (VCDs) induce or assist pe-
nile erection by drawing mainly venous blood flow into 
the cavernous space through negative pressure. A con-
strictive band placed at the base of the penis prevents 
the backflow to maintain the erection. The effects of 
VCDs do not require an intact nervous control and thus 
can also be applied to men who have not undergone 
nerve-sparing prostatectomy.
Studies have shown significant shrinkage of penile 
length after RP.18,19 These authors suggest that hypoxia 
leads to increased expression of transforming growth fac-
tor β and collagen I and III fibers. The rationale for the 
early use of VCDs following RP is thus to preserve penile 
length and girth via passive penile erection with the use 
of the device, and subsequent cavernous fibrosis fol-
lowed by veno-occlusive dysfunction may be prevented. 
One prospective but nonrandomized study conducted at 
the Cleveland Clinic consisted of 74 patients (Group 1) 
using VCDs daily for 9 months and 35 patients (Group 2) 
under observation without any early erectogenic treat-
ment.20 In Group 1, 32% of the patients reported return of 
natural erections, with 17% having erections sufficient for 
sexual intercourse. In Group 2, 37% of the patients re-
gained spontaneous erections and only 11% had erections 
sufficient for successful vaginal intercourse. Regarding 
the effect of VCDs on penile length, the men in Group 1 
experienced significantly less penile shrinkage.
The timing to initiate VCDs may also be of impor-
tance. Kohler et al.21 randomized 28 men to either early 
use of VCD (1 month after RP) or delayed use of VCD 
(6 months after RP). The results showed that men who 
used VCDs early had better erectile function and less 
penile shrinkage as compared with men who delayed 
the use of VCDs.
4.  Phosphodiesterase Type 5 Inhibitors for 
Penile Rehabilitation
The introduction of phosphodiesterase type 5 (PDE5) 
inhibitors in 1998 revolutionized the treatment of ED. 
Ease of use, acceptable efficacies and relatively high 
safety profiles have made this kind of ED treatment pop-
ular worldwide. These drugs have also been investigated 
in a number of clinical studies for their applicability for 
penile rehabilitation.
Schwartz et al.22 conducted a pioneer study to perform 
penile rehabilitation with the use of a PDE5 inhibitor. Forty 
men who had undergone nerve-sparing prostatectomy 
received percutaneous biopsies of the cavernous tissue 
before the operation. After the operation, they were di-
vided into two groups to receive either 50 or 100 mg of 
sildenafil every other night. They underwent percutane-
ous biopsies of the cavernous tissue again at 6 months. 
The results showed that the 50-mg group had no loss of 
cavernous smooth muscle following the operation, and 
the 100-mg group even had increased smooth muscle 
content.
Bannowsky et al.23 conducted a randomized trial to 
investigate the role of daily sildenafil use in penile reha-
bilitation. Forty-three men who underwent nerve-sparing 
RP were enrolled and provided data for the preoperative 
International Index of Erectile Function (IIEF) scores. 
After the catheter was removed, the men underwent 
Rigiscan testing to detect nocturnal tumescence. Of the 
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43 men, 41 were found to have spontaneous erections on 
Rigiscan. These men were randomized to receive either 
daily sildenafil or no treatment. Erectile function was eval-
uated with IIEF at 6, 12, 24, 36 and 52 weeks. The results 
showed that the treatment group had significantly higher 
IIEF scores by 36 and 52 weeks as compared with the no-
treatment group. Forty-seven percent of the daily treat-
ment group, as compared with 28% of the control group, 
were able to achieve spontaneous, unassisted erection 
sufficient for penetration.
McCullough et al.24 conducted another randomized, 
double-blinded, placebo-controlled study to evaluate the 
efficacy of daily sildenafil for penile rehabilitation. This 
study included 54 men who had undergone bilateral 
nerve-sparing RP and had normal preoperative erectile 
function. The men were randomized to receive nightly 
100 mg of sildenafil (18 men), 50 mg of sildenafil (17 
men) or placebo (19 men). The results were analyzed at 
16, 28 and 40 weeks. After 40 weeks, all medications 
were discontinued and the results were analyzed at 
48 weeks. At each point, the participants were evaluated 
by nocturnal penile tumescence and rigidity and IIEF. The 
study found that the treatment groups had better erection 
than the placebo group. Additionally, the 100-mg group 
experienced continued improvement after sildenafil was 
discontinued, while the 50-mg group experienced decline 
in erectile function. The men on daily sildenafil also had 
better return of spontaneous, unassisted erection suffi-
cient for intercourse compared with the men on placebo.
Besides sildenafil, other PDE5 inhibitors had also 
been tried to enhance recovery of erectile function in 
men following nerve-sparing RP. In one large, rand-
omized, double-blind, multicenter study, Montorsi et al.25 
showed that although vardenafil was effective in treat-
ing post-RP ED, either nightly or on-demand use of var-
denafil in a period of night months did not benefit the 
recovery of erectile function in men following bilateral 
nerve-sparing RP.
To date, most relevant studies indicate that PDE5 in-
hibitors have a role in penile rehabilitation for men after 
RP. In general, these drugs are safe and well tolerated 
when used for penile rehabilitation; yet further studies 
are needed to determine the proper dosage and the cor-
rect application of these drugs for this particular use.
5.  Combination Therapies for Penile 
Rehabilitation
Theoretically, all of the above-mentioned treatment mo-
dalities can be used in combination for penile rehabilita-
tion. Only few studies have examined the feasibilities of 
combination therapies. Nandipati et al.26 used the com-
bination of ICI therapy and PDE5 inhibitor to implement 
penile rehabilitation in 22 men who underwent nerve-
sparing prostatectomy. All men received sildenafil 50 mg 
daily. For ICI, 18 patients received ICI of prostaglandin E1 
and four received Trimix ICI two to three times per week. 
These men were then analyzed at 3, 6, 9 and 12 months 
using IIEF. Of the 18 men using prostaglandin E1, 12 could 
lower the dosage, while one of the four men on Trimix 
could lower the dose. Six months later, 21 of 22 patients 
were sexually active, of which 12 men used ICI alone and 
nine men used combination therapy. Eleven of the 22 
men had return of spontaneous erection, yet no men 
graded the erections as being sufficient for penetration. 
The authors concluded that the addition of sildenafil 
could reduce the doses of vasoactive agents used for ICI 
to achieve sufficient erections.
6.  Real-life Application of Penile Rehabilitation
Several concerns are worth mentioning when practicing 
real-life penile rehabilitation. If nerve-sparing attempts 
are not incorporated into the operation, then PDE5 in-
hibitor application will most likely be ineffective. For these 
men, other options like ICI of vasoactive agents, VCDs or 
the combination of both should be considered first for 
penile rehabilitation. Secondly, cost of the treatment mo-
dalities can be high, which may be a problem for some 
men who need long-term use of these treatments. Com-
bination therapies will cost even more. Thirdly, motiva-
tion and compliance of the patients may significantly 
affect the effects of penile rehabilitation, and patient 
education before and after surgery may be of help to 
overcome these obstacles. Finally, clinical evidence re-
garding penile rehabilitation is still lacking presently for 
the setting up of proper guidelines. Although results of 
large-scale, placebo-controlled, randomized studies can 
offer precious information on penile rehabilitation, recruit-
ment of patients may be quite difficult if the patients are 
not aware that delayed penile rehabilitation can be det-
rimental to recovery of the erectile function.
7. Conclusion
ED after RP can significantly affect the quality-of-life issue 
of many men and their sexual partners. Various standard 
treatment options for ED, like ICI of vasoactive agents, 
VCDs and oral PDE5 inhibitors, can be safely used for 
penile rehabilitation to help the patients have better 
chances of restoring erectile function. Evidence has indi-
cated that these attempts are worthwhile, and use of 
combination treatment modalities may be even more 
effective in certain men. To optimize the effects of pe-
nile rehabilitation, proper performance of nerve-sparing 
procedures may sometimes be crucial. Currently, there 
are still no generally accepted guidelines on penile reha-
bilitation, and factors like patient motivation and expecta-
tions, ease of use, availability of treatment, and cost must 
all be taken into consideration when making rehabilita-
tion plans. Large-scale, randomized, placebo-controlled 
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clinical trials with adequate follow-up periods are neces-
sary to offer in-depth information to help set up appro-
priate guidelines for penile rehabilitation.
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